|
NEWS, EVENTS, and DEADLINES
June 13, 2024
| |
NJ ACTS Renewed for 7 Years | |
 |  | The New Jersey Alliance for Clinical and Translational Science (NJ ACTS) has received a 7-year award from the National Institutes of Health under its Clinical and Translational Sciences (CTSA) Program. This award funds the NJ ACTS Hub and provides for the programs and services of NJ ACTS to its affiliates, Rutgers, Princeton University, the New Jersey Institute of Technology and RWJ Barnabas Health. Receipt of this award is an important accomplishment. It means that our programs, including those that support clinical and translational research and science, can evolve seamlessly and without interruption from the initial award (2019-2024) to the new one. These include building additional services for the community, identifying and reducing administrative and regulatory barriers, harnessing AI/ML and informatics resources, creating a genomics research and education service, developing creative training programs, including coordinator badging, and recognizing your work and accomplishments at events, such as the Clinical Trials Day.
In addition, the Hub award allows us to compete for key additional programs, including the K12 Career Development Award, the R25 Research Education Grant, and the T32 Pre- and Post-doctoral Training Awards. We will completely celebrate when those are in place as well.
The leadership of NJ ACTS thanks you, the entire NJ ACTS research community, for your support and commitment to excellence in research.
| |
Upcoming NJ ACTS, Rutgers, Princeton and NJIT Events | |
|
Rutgers Health Faculty Development Symposium
How to Succeed in Academia Despite Hurdles
June 13, 2024
11 am - 1 pm
| |
|
Lessons Learned from a
Long Career in Academia
| |
Darrell Kirch, MD
President Emeritus
Association of American Medical Colleges
| |
|
Keys to Success in
Medicine and Life
| |
Luanne Thorndyke, MD
Affiliate Professor of Medicine
University of Massachusetts
| |
|
Rutgers Innovation Awards 2024
The Rutgers Office for Research is inviting nominations for the 2024 Innovation awards which recognize outstanding achievements by Rutgers researchers who have developed a breakthrough idea, process, or technology with transformational potential to improve lives and create economic value. Honorees will be celebrated at a event in September. Read more.
Apply yourself directly or nominate your research faculty, research staff, postdocs, clinical fellows or students (graduate and undergraduate).
Apply by June 15, 2024
| |
Andrew Boreland named an NIH Outstanding Scholar in Neuroscience Award Program (OSNAP) Recipient
NJ ACTS congratulates Dr. Boreland on being named an award recipient for The Outstanding Scholars in Neuroscience Award Program (OSNAP), designed to recognize those who are conducting exceptional neuroscience research across the nation and have great academic potential in their scientific training.
Boreland was a member of the 2020 cohort for the NJ ACTS TL1 Fellows Program.
| |
|
Rutgers and Princeton among Top 100 U.S. Universities for Utility Patents
Annually, the National Academy of Inventors compiles a list based on data from the US Patent and Trademark Office. The Top 100 U.S. Universities List recognizes U.S. universities that play a large role in advancing innovation and invention in the United States.
Read more from the National Academy of Inventors (NAI)
| |
|
Funding for Inventions
The Rutgers Office for Research provides funding and mentoring to support inventors in the process of commercializing their inventions.
There are two major funding opportunities available to Rutgers inventors: TechAdvance® and HealthAdvance®:
Click on the Programs above to learn more!
| |
Guidance on the Use of AI at Rutgers | | |
|
Appropriate Use of Artificial Intelligence (AI)
in Academia and Research
As the AI landscape continues to evolve, guidance on the use of AI at Rutgers is critically important. The current guidance is available at the Artificial Intelligence at Rutgers.
| | |
NCATS, NIH, and Federal News and Events | |
Collaboration Webinars from the
Hear from CTSA TIN experts on various trial-related topics to improve your project.
| |
|
Innovations in action: Leveraging the Epic platform to accelerate patient-centric recruitment and improve representation
Epic is an electronic health records (EHR) platform that has a strong commitment to innovation through iterative collaboration with our b community of stakeholders. Both past successes and new opportunities to impact the trial landscape will be discussed.
July 1, 2024
12 pm
| |
|
Striking the Balance: Integrating Innovative Technology and Personalized Engagement in Clinical Trials Recruitment
This webinar will discuss ways to overcome challenges using the UC Davis Clinical Trials Recruitment Program model. Our goal is that attendees will gain practical strategies, toolkits, and fresh ideas for clinical trial participant identification and engagement.
September 18, 2024
12 pm
| |
National Institutes of Health (NIH) - Addressing Ethical, Legal, and Social Implications (ELSI) in Human Genetics and Genomics - Seeking to broaden the types of knowledge, skills, expertise, experience, and perspectives brought to bear in the field of ELSI research. See NIH’s Notice of Intent to Publish NOT-HG-24-027. Funding will be released in July. Contact njacts@rbhs.rutgers.edu if you are interested. | |
NJ ACTS is a partnership between Rutgers, NJIT and Princeton. NJ ACTS advances clinical and translational science to develop new therapies and treatments and improve population health. | |
|
This newsletter is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number, UM1TR004789 to Rutgers University. The content is solely the responsibility of the authors and does not represent the official views of the NIH.
New Jersey Alliance for Clinical and Translational Science
89 French St., Suite 4211
New Brunswick, NJ
Copyright 2020 New Jersey Alliance for Clinical and Translational Science, all rights reserved
Send story ideas to NJACTS@rbhs.rutgers.edu
UL1TR003017 (pre-5/1/2024), UM1TR004789 (starting 5/1/2024), KL2TR003018 and TL1TR003019
| | | | |
